Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

oncolytic viruses

18 SWITCHED ONcology: The Big Communication

Matching unprecedented clinical advances in immuno-oncology with transformative communication

Havas Lynx

- PMLiVE

Boehringer beefs up biologics capacity with €230m investment

New facility to focus on analytical and process development and manufacturing of biologics for trials.

- PMLiVE

Daily Brief: Andrew Witty’s replacement on Accelerated Access initiative, Blincyto gains full EU approval and more

The latest news from across pharma, biotech and healthcare

Medical information in precision medicine

Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine.

Blue Latitude Health

- PMLiVE

ICER says price of Amgen/Novartis’ Aimovig is OK – if used last-line

Recommends the drug should only be used in patients who have exhausted other prevention options

EphMRA Annual Conference 2018

Visit us on stand number 20

Research Partnership

- PMLiVE

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

A rapid round-up of pharma, biotech and healthcare news

- PMLiVE

Novartis, Amgen set low price for first CGRP migraine drug

Aimovig has a list price of $6,900 per year

Boehringer Ingelheim headquarters

Boehringer partners with Bactevo on drug discovery

Bactevo will use its TIME platform to identify small molecule lead compounds

Boehringer partners with Bactevo on drug discovery

Bactevo will use its TIME platform to identify small molecule lead compounds

AstraZeneca AZ

AZ’s immuno-oncology combo fails another lung cancer trial

Latest failure casts doubt on company’s CTLA4 drug

- PMLiVE

Amgen and Novartis migraine drug hits the mark again

Aimovig will become the first CGRP receptor-targeting drug if it reaches market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links